Delveinsight

DECEMBER 29, 2020

Relugolix is a once-daily, oral gonadotropin-release hormone (GnRH) receptor antagonist. Audentes Therapeutics’ ASPIRO Trial Free to Proceed. The ASPIRO trial is a two-part, open-label ascending dose study, and is examining the safety and preliminary efficacy of AT132 in children with XLMTM younger than five years old.

Trials 52

Trials Drugs Hormones Radiology 52

XTalks

FEBRUARY 8, 2024

According to AstraZeneca, the drug had strong demand across all of its approved indications and was further supported by recent guideline updates from cardiology societies. for a 2-pen package (0.6 & 1.2 for a 3-pen package (1.8 This performance exceeded Wall Street’s expectations by 20 percent. mg doses), or $815.27

Sales 52

Sales Insulin FDA Approval Drugs 52

XTalks

AUGUST 2, 2023

2) Paxlovid (nirmatrelvir/ritonavir) Paxlovid is a dual-packaged oral medication for the treatment of COVID-19. 5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. billion in 2022. billion in 2022.

Sales 98

Sales Manufacturing FDA Approval Life Science 98